

JOB OFFER		
REFERENCE	OPENING DATE	DEADLINE
2021.309	20/12/2023	29/12/2023
PROFILE REQUIREMENTS		
EXCLUSIVE REQUIREMENTS: (1)		
ACADEMIC DEGREE	Degree + official master's degree/equivalent related to health sciences, biomedical and/or biochemistry. (<i>Exclusive requirement: provide justification with the application.</i>)	
VALUED MERITS /SKYLLS		
EXPERIENCE	Knowledge of techniques related to cell biology, flow cytometry, molecular biology and proteomics, in vivo studies...	
OTHER REQUIREMENTS	Average grade of the transcript higher than 7.5.	
LANGUAGES	English.	
CONTRACT INFORMATION		
TYPE OF CONTRACT	EXPECTED INCORPORATION DATE	JOB STATUS
Indefinite in accordance with Article 23 Bis of Law 14/2011, of June 1, 2011, on Science, Technology and Innovation.	January 2024	Complete 1575 hours per year (approx. 35 h/week)
ANNUAL GROSS SALARY		DURATION OF THE CONTRACT
26.066,88 €		Indefinite, linked to the duration of the project and economic availability based on RDL8/2022
WORK LOCATIONS		UNIT/DEPARTMENT
IDIVAL		Hematologic Neoplasms and Hematopoietic Progenitor Transplantation
JOB DETAILS		
OFFER DESCRIPTION		
Research support technician		
FUNCTIONS		
<ul style="list-style-type: none"> - The project to be developed involves interdisciplinary training in different areas such as molecular biology, flow cytometry, bioinformatics, in vivo studies, etc. and participation in international projects. - Development of the doctoral thesis. 		
PRINCIPAL INVESTIGATOR / RESPONSABLE	RESEARCH GROUP	RESEARCH PROJECT
Dr. Enrique M. Ocio San Miguel	Hematologic and Hematopoietic Progenitor Transplantation.	2021.309: Randomized phase 3 study comparing teclistamab in combination with daratumumab s.c. (Tec-Dara) vs. daratumumab s.c., pomalidomide and dexamethasone (DPd) or daratumumab s.c., bortezomib and dexamethasone (DVd) in patients with multiple myeloma refractory to RSV-related disease progression risk.

RECRUITMENT INFORMATION				
SELECTION PROCESS STAGES (2)				EMPLOYMENT EXCHANGE
1. Pre-selection 2. Interview: minimum score for access to the interview phase: 40 points 3. Report of the Selection Board 4. Resolution				NOT
SELECTION BOARD				
<ul style="list-style-type: none"> • Dr. Enrique M. Ocio San Miguel, Project's Main Researcher • Galo Peralta, IDIVAL's Management Director • Patricia Álvarez-Ingelmo, IDIVAL Human Resources Coordinator (She will act as registrar of the selection board). 				
VALUATION OF MERITS				
MERITS	EVALUATION	SCORE		MAXIMUM
Knowledge of techniques related to cell biology, flow cytometry, molecular biology and proteomics, in vivo studies...	CV	Compliance with the requirement	YES/ NO	40
Average grade of the transcript higher than 7.5.	CV	Compliance with the requirement	YES/ NO	10
English.	Accreditation	Level	B2: 5 points C1: 10 points	10
FINAL SCORE				
MAXIMUM TOTAL SCORE BY MERITS				60
MAXIMUM TOTAL SCORE IN INTERVIEW				40
MAXIMUM TOTAL SCORE				100

(1) Not subsanable

(2) See duration of each phase in the document "Selection Process"

In compliance with the provisions of Article 11 of Organic Law 3/2018, you are informed that the person responsible for the processing of your personal data is the MARQUES DE VALDECILLA INSTITUTE OF INVESTIGATION FOUNDATION (IDIVAL), your data will be treated in order to be treated to the extent that they were necessary or convenient for the development of the legal relationship established between the parties. You can exercise your rights of access, rectification, deletion, opposition, portability or limitation of the treatment, by contacting the IDIVAL FOUNDATION at the following address: AVDA. CARDENAL HERRERA ORIA, S / N 39007, SANTANDER. More information at www.idival.org/es/Política-de-Privacidad